Do analysts rate GALT or ZSQR?

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 252.56%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to GALT or CRMD?

In the previous week, Galectin Therapeutics had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Galectin Therapeutics and 2 mentions for CorMedix. Galectin Therapeutics' average media sentiment score of 0.00 equaled CorMedix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, RLMD or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A

Is RLMD or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Galectin Therapeutics N/A N/A -164.69%

Does the media prefer RLMD or GALT?

In the previous week, Relmada Therapeutics had 13 more articles in the media than Galectin Therapeutics. MarketBeat recorded 17 mentions for Relmada Therapeutics and 4 mentions for Galectin Therapeutics. Relmada Therapeutics' average media sentiment score of 1.05 beat Galectin Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, GALT or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is GALT or DSGN more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Design Therapeutics N/A -33.07% -31.29%

Does the media prefer GALT or DSGN?

In the previous week, Galectin Therapeutics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 1 mentions for Design Therapeutics. Galectin Therapeutics' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GALT or ALLO more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Allogene Therapeutics N/A -56.45% -40.36%

Does the media favor GALT or ALLO?

In the previous week, Galectin Therapeutics had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 1 mentions for Allogene Therapeutics. Galectin Therapeutics' average media sentiment score of 0.00 beat Allogene Therapeutics' score of -1.74 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative

Galectin Therapeutics (GALT) Competitors

$3.12 +0.32 (+11.43%)

As of 04:00 PM Eastern

Compare

GALT vs. ZSQR, CRMD, RLMD, DSGN, and ALLO

Should you buy Galectin Therapeutics stock or one of its competitors? MarketBeat compares Galectin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galectin Therapeutics include Coeptis Therapeutics (ZSQR), CorMedix (CRMD), Relmada Therapeutics (RLMD), Design Therapeutics (DSGN), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does Galectin Therapeutics compare to Coeptis Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Galectin Therapeutics had 4 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 0 mentions for Coeptis Therapeutics. Galectin Therapeutics' average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score.

Company	Overall Sentiment
Galectin Therapeutics	Neutral
Coeptis Therapeutics	Neutral

Coeptis Therapeutics has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Coeptis Therapeutics	$1.36M	505.98	-$11.92M	-$2.52	N/A

Galectin Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.22, indicating that its stock price is 122% less volatile than the broader market.

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 252.56%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galectin Therapeutics has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Galectin Therapeutics' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Galectin Therapeutics beats Coeptis Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to CorMedix?

Galectin Therapeutics (NASDAQ:GALT) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Galectin Therapeutics had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Galectin Therapeutics and 2 mentions for CorMedix. Galectin Therapeutics' average media sentiment score of 0.00 equaled CorMedix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
CorMedix	$311.71M	2.16	$163.05M	$2.13	4.04

CorMedix has a net margin of 45.25% compared to Galectin Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Galectin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
CorMedix	45.25%	45.57%	24.76%

Galectin Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Galectin Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 252.56%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 74.42%. Given Galectin Therapeutics' higher possible upside, equities analysts plainly believe Galectin Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

CorMedix beats Galectin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Galectin Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Galectin Therapeutics	N/A	N/A	-164.69%

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

In the previous week, Relmada Therapeutics had 13 more articles in the media than Galectin Therapeutics. MarketBeat recorded 17 mentions for Relmada Therapeutics and 4 mentions for Galectin Therapeutics. Relmada Therapeutics' average media sentiment score of 1.05 beat Galectin Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 77.25%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 252.56%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Relmada Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

Relmada Therapeutics beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Design Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Galectin Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Galectin Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Design Therapeutics	N/A	-33.07%	-31.29%

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Galectin Therapeutics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 1 mentions for Design Therapeutics. Galectin Therapeutics' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 252.56%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 20.09%. Given Galectin Therapeutics' higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Summary

Galectin Therapeutics beats Design Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Galectin Therapeutics compare to Allogene Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Galectin Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Galectin Therapeutics has higher earnings, but lower revenue than Allogene Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Allogene Therapeutics	$20K	35,723.03	-$190.89M	-$0.77	N/A

Galectin Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Galectin Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 252.56%. Allogene Therapeutics has a consensus price target of $8.52, indicating a potential upside of 311.70%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Galectin Therapeutics had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 1 mentions for Allogene Therapeutics. Galectin Therapeutics' average media sentiment score of 0.00 beat Allogene Therapeutics' score of -1.74 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Allogene Therapeutics beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$184.40M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-7.61	18.43	24.92	23.98
Price / Sales	N/A	327.41	528.51	109.04
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	-1.57	4.11	10.79	6.50
Net Income	-$30.84M	$64.45M	$3.56B	$336.88M
7 Day Performance	18.18%	2.24%	1.67%	-0.22%
1 Month Performance	24.80%	1.04%	0.43%	0.77%
1 Year Performance	25.81%	30.05%	32.84%	31.57%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	1.4344 of 5 stars	$3.12 +11.4%	$11.00 +252.6%	+15.7%	$184.40M	N/A	N/A	9	News Coverage Analyst Forecast Gap Down High Trading Volume
ZSQR Coeptis Therapeutics	0.1677 of 5 stars	$13.36 +4.6%	N/A	+94.6%	$687.11M	$1.36M	N/A	2	Gap Down
CRMD CorMedix	2.9758 of 5 stars	$8.55 -0.4%	$15.00 +75.4%	-35.2%	$670.83M	$311.71M	4.01	30
RLMD Relmada Therapeutics	2.2926 of 5 stars	$6.40 +0.4%	$12.00 +87.6%	+915.5%	$670.35M	N/A	N/A	10	Positive News Analyst Revision Gap Down
DSGN Design Therapeutics	1.8117 of 5 stars	$10.71 -3.9%	$16.50 +54.1%	+266.3%	$669.26M	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. ZSQR, CRMD, RLMD, DSGN, and ALLO

How does Galectin Therapeutics compare to Coeptis Therapeutics?

Summary

How does Galectin Therapeutics compare to CorMedix?

Summary

How does Galectin Therapeutics compare to Relmada Therapeutics?

Summary

How does Galectin Therapeutics compare to Design Therapeutics?

Summary

How does Galectin Therapeutics compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. ZSQR, CRMD, RLMD, DSGN, and ALLO

How does Galectin Therapeutics compare to Coeptis Therapeutics?

Do insiders and institutionals have more ownership in GALT or ZSQR?

Does the media refer more to GALT or ZSQR?

Which has stronger valuation & earnings, GALT or ZSQR?

Which has more volatility & risk, GALT or ZSQR?

Do analysts rate GALT or ZSQR?

Is GALT or ZSQR more profitable?

Summary

How does Galectin Therapeutics compare to CorMedix?

Does the media refer more to GALT or CRMD?

Which has higher earnings and valuation, GALT or CRMD?

Is GALT or CRMD more profitable?

Which has more volatility & risk, GALT or CRMD?

Do insiders and institutionals hold more shares of GALT or CRMD?

Do analysts rate GALT or CRMD?

Summary

How does Galectin Therapeutics compare to Relmada Therapeutics?

Is RLMD or GALT more profitable?

Do insiders and institutionals have more ownership in RLMD or GALT?

Which has better valuation and earnings, RLMD or GALT?

Does the media prefer RLMD or GALT?

Do analysts recommend RLMD or GALT?

Which has more risk & volatility, RLMD or GALT?

Summary

How does Galectin Therapeutics compare to Design Therapeutics?

Which has more volatility and risk, GALT or DSGN?

Is GALT or DSGN more profitable?

Do insiders & institutionals hold more shares of GALT or DSGN?

Does the media prefer GALT or DSGN?

Do analysts rate GALT or DSGN?

Which has stronger earnings and valuation, GALT or DSGN?

Summary

How does Galectin Therapeutics compare to Allogene Therapeutics?

Which has more volatility and risk, GALT or ALLO?

Which has higher valuation and earnings, GALT or ALLO?

Is GALT or ALLO more profitable?

Do analysts recommend GALT or ALLO?

Does the media favor GALT or ALLO?

Do insiders & institutionals have more ownership in GALT or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools